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BACKGROUND: The first UKCCCR Anal Cancer Trial (1996) demonstrated the benefit of chemoradiation over radiotherapy (RT) alone
for treating epidermoid anal cancer, and it became the standard treatment. Patients in this trial have now been followed up for a
median of 13 years.
METHODS: A total of 577 patients were randomised to receive RT alone or combined modality therapy using 5-fluorouracil and
mitomycin C. All patients were scheduled to receive 45Gy by external beam irradiation. Patients who responded to treatment were
recommended to have boost RT, with either an iridium implant or external beam irradiation. Data on relapse and deaths were
obtained until October 2007.
RESULTS: Twelve years after treatment, for every 100 patients treated with chemoradiation, there are an expected 25.3 fewer patients
with locoregional relapse (95% confidence interval (CI): 17.5–32.0 fewer) and 12.5 fewer anal cancer deaths (95% CI: 4.3–19.7
fewer), compared with 100 patients given RT alone. There was a 9.1% increase in non-anal cancer deaths in the first 5 years of
chemoradiation (95% CI þ3.6 to þ14.6), which disappeared by 10 years.
CONCLUSIONS: The clear benefit of chemoradiation outweighs an early excess risk of non-anal cancer deaths, and can still be seen
12 years after treatment. Only 11 patients suffered a locoregional relapse as a first event after 5 years, which may influence the choice
of end points in future studies.
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Epidermoid anal cancer is relatively uncommon, with B750 cases
per year in the United Kingdom and 4750 in the United States
(Cancer Research UK, 2008; Jemal et al, 2009). The first report,
published in 1996, showed that radiotherapy (RT) plus chemo-
therapy (5-fluorouracil and mitomycin C) was superior to RT
alone (UKCCCR Anal Cancer Trial Working Party, 1996).
Chemoradiation reduced the risk of local failure by 46%
(Po0.0001) and the risk of death from anal cancer by 29%
(P¼0.02). As a consequence of this trial and of two other phase III
studies (Flam et al, 1996; Bartelink et al, 1997), the combination of
chemotherapy–radiation became the international standard treat-
ment. The first UKCCCR Anal Cancer Trial (ACT I) was intended
to be both pragmatic and nationally inclusive. Patients with anal
margin cancers and T1 cancers, normally excluded from other
randomised trials because of their more favourable prognosis,
formed 23 and 13%, respectively, of the population within the trial.
The first ACT I results were based on a median follow-up of
3.5 years, but we continued to collect data on relapse and death.
MATERIALS AND METHODS
A total of 585 patients were randomised to ACT I between
December 1987 and March 1994 from 56 centres (53 in the United
Kingdom and 3 in South Africa, Portugal and Italy). Details have
been previously reported (UKCCCR Anal Cancer Trial Working
Party, 1996).
Patients
Eligible patients had epidermoid carcinoma (squamous, basaloid
or cloacogenic) of the anal canal or margin. Patients were mainly
clinically rather than radiologically staged. The tumour was staged
using the 1985 UICC TNM classification (Spiessl et al, 1985).
Staging for distant disease was carried out according to local
practice.
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Patients were randomised to RT alone or RT combined with
chemotherapy, i.e., combined modality therapy (CMT), using a
1:1 allocation ratio. Radiotherapy consisted of a central axis dose
of 45Gy, delivered with anterior and posterior opposing fields. The
dose was administered in 20 or 25 fractions over 4 or 5 weeks
by external beam irradiation. Combined modality therapy had
the same radiotherapy regimen combined with 5-fluorouracil
(1000mgm
 2 for 4 days or 750mgm
 2 for 5 days) by continuous
intravenous infusion during the first and final weeks of radio-
therapy, and mitomycin C (12mgm
 2) as a single intravenous
bolus injection on day 1 of the first cycle of chemotherapy. Patients
judged to be good responders by 6 weeks after completing
treatment were recommended to have further radiotherapy
(boost), with either an iridium implant to 25Gy (10Gy per day)
or external beam irradiation giving 15Gy in six fractions.
End points
Outcome measures were time to first locoregional relapse; relapse-
free survival (RFS: time to any first relapse or death); colostomy-
free survival (time to colostomy or death); overall survival (OS);
death from anal cancer; and death from other causes. Colostomy-
free survival was examined separately from locoregional failure. All
colostomies, from disease and morbidity, were included.
Overall, 45% of deaths among those with known causes of death
were not due to anal cancer; therefore, patients whose cause of
death was unknown were classified as dying because of causes
other than anal cancer. Fifteen patients who had metastases at
entry to the trial were classified as having a distant relapse at the
time of randomisation (six RT alone, nine CMT). Patients with
pelvic or local relapse were grouped as having locoregional relapse.
Toxicities occurring or persisting more than 6 months after
completing initial radiotherapy were defined as late morbidity.
These were not scored or quantified. In 2007, we contacted all
centres to request the following: the date and cause of death; the
date of first relapse (local, pelvic or distant); and the date when the
patient was last seen alive if they had not died. Death notifications
in the United Kingdom were also received from the Office for
National Statistics. The analysis reported here is based on data
collected up to October 2007, and data on colostomies and late
morbidity up to 2000.
Statistical considerations
Kaplan–Meier survival curves and Cox regression were used to
compare treatment groups. Hazard ratios (HRs) are expressed as
CMT vs RT alone. The event rate in the CMT arm and absolute risk
differences were calculated by applying the HR to the event rate in
the RT alone group. Proportional hazards between treatments were
assumed (i.e., the ratio of risks for having an event is constant over
the study period). When this assumption did not hold, the
difference in the event rate was estimated using the two observed
rates. Statistical analyses were performed using Stata (version 10).
In the original analysis, several criteria were combined to define
local failure: (i) the date of biopsy or clinical determination of
residual/recurrent locoregional disease; (ii) the date of colostomy
forming surgery for treatment-related morbidity; or (iii) 6 months
after the end of treatment if a pretreatment colostomy had not
been closed. Local failure was assessed from 6 weeks after initial
treatment. In this paper, only treatment failures due to disease
within the anal canal, margin or pelvic region were included.
In the analysis of time to first locoregional relapse, four patients
who were recorded as having a distant relapse before a
locoregional relapse were censored at the date of distant relapse.
Patients who had any relapse before 6 weeks after the end of initial
treatment were censored at the date of first relapse. For the
analysis of RFS, patients with both a locoregional and distant
relapse recorded on the same date are treated as having an event.
RESULTS
Of the 577 eligible patients randomised, 285 were allocated to receive
RT alone and 292 CMT. Eight patients were found to be ineligible
and were excluded from both previous and current analyses (seven
patients did not have anal cancer and the other patient had
previously undergone anorectal excision). The median follow-up was
13.1 years, representing 3685 patient-years in total (based on all
patients and censoring those who had died); maximum follow-up
was 18.9 years. We did not have data on 93 patients from October
2005. In the original report of ACT I, there were nine patients
without any follow-up data, but now these data are available.
Locoregional failure
In all, 263 patients had locoregional relapse as their first event
(Table 1). Of 560 patients, 239 had locoregional relapse (153
radiotherapy, 86 CMT), after excluding 17 (8 RT alone, 9 CMT)
who did not survive 6 weeks beyond the end of initial radiotherapy
(or when it was scheduled to end). Combined modality therapy was
associated with a reduction in the risk of locoregional relapse, HR
0.46 (95% confidence interval (CI): 0.35–0.60), Po0.001). By 5 years,
t h ea b s o l u t er i s kd i f f e r e n c ew a s 24.8% (Appendix Table A1 and
Figure 1A). After 5 years, only 11 patients (five RT alone, six CMT;
Appendix Table A2) developed locoregional relapse as their first
event and hence the risk difference remained B25% thereafter.
Relapse-free survival
A total of 452 patients died from any cause, or relapsed (Table 1).
Combined modality therapy was associated with a reduction in the
risk of relapsing or dying (HR 0.70, 95% CI 0.58–0.84, Po0.001).
Table 1 Type of event, by treatment
Event
RT alone
(N¼285)
CMT
(N¼292)
First event: relapse or death
Locoregional relapse
a 155 94
Locoregional relapse and distant
relapse
a
77
Distant relapse 21 29
Death 56 83
Any event 239 213
Cause of death
Anal cancer 125 93
New cancer 18
b 34
c
Treatment related 5 6
Other causes 50 64
Cardiac 18 20
Cerebrovascular accident 5 6
Other vascular 3 3
Infection 15 17
Pulmonary 5 9
Other 4 9
Unknown 7 3
Total 205 200
Abbreviations: CMT¼combined modality therapy; RT¼radiotherapy.
aWithin 6
weeks following the end of initial treatment, there were two RT-alone patients and
seven CMT patients who died, and nine RT-alone patients and ten CMT patients
who had a relapse.
bLung (7), unknown primary (4), ureter (1), oesophagus (1),
liver (1), laryngeal (1), gastric (1), large bowel (1), unknown (1).
cLung (17), leukaemia
(3), breast (2), rectal (1), prostate (1), bladder (1), cerebral glioma (1),
neuroendocrine (1), colon (1), myelodysplasia (1), ovary (1), oesophagus (1), larynx
(1), abdomen (1), unknown primary (1).
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at 5 years (Appendix Table A1 and Figure 1B). After 5 years, only
17 patients relapsed and 100 died; the risk difference remained
fairly constant: þ12% at 12 years.
Combined modality therapy was associated with a reduction in
the risk of any relapse or death due to anal cancer (HR 0.61, 95%
CI 0.49–0.76, Po0.001). The absolute risk difference remained
similar after 2 years, and at 12 years was  18.0% (95% CI:  10.2 to
 25.4%) in favour of CMT.
Colostomy-free survival
Combined modality therapy was associated with a decrease in the
risk of having a colostomy or death (HR 0.76, 95% CI 0.63–0.91,
P¼0.004). The absolute risk difference remained B10% favouring
CMT between 5 and 12 years (Appendix Table A1 and Appendix
Figure A1).
Late morbidity
There was no evidence of a treatment difference for ulcers/
radionecrosis, anorectal, genitourinary or skin-related late
morbidities (Appendix Table A3).
Overall survival and deaths from anal cancer
There were 405 deaths, 54% (218) from anal cancer (Table 1). The
death rate was 14% lower in the CMT group, HR 0.86 (95% CI:
0.70–1.04, P¼0.12). Five years after randomisation, the absolute
risk difference of dying was 5.1% lower in the CMT group, and this
remained similar up to 12 years (Appendix Table A1 and Figure 2).
The median survival was 7.6 years (95% CI 5.9–9.9 years) in the
CMT group and 5.4 years (95% CI 3.6–6.8 years) in those receiving
RT alone.
There was a statistically significant reduction in the risk of dying
from anal cancer, HR 0.67 (95% CI 0.51–0.88, P¼0.004). Only 29
(13%) deaths from anal cancer occurred after 5 years. The absolute
risk difference in death from anal cancer observed at 5 years
(11.3% in favour of CMT) was similar to that observed at 12 years
(12.5%; Appendix Table A1 and Figure 3). Even when we classified
the 10 unknown deaths as being due to anal cancer, the results did
not change – HR 0.66 (95% CI: 0.50–0.85).
Deaths other than from anal cancer
The assumption of proportional hazards did not hold for the first
10 years when examining deaths other than from anal cancer;
Figure 4 (test for proportional hazards P¼0.01). There were more
non-anal cancer deaths in the CMT group in the first 10 years after
randomisation (67 CMT vs 48 RT alone), with a maximum
difference at about 5 years (þ9.1%, 95% CI þ3.6 to þ14.6%,
P¼0.001). The effect almost disappeared by 10 years and
remained so for the rest of the follow-up period. Appendix
Table A2 provides details of the cause of death and when they
occurred. During the first 5 years, many of these deaths (43 CMT
vs 19 RT alone) were cardiovascular (15 vs 8 deaths, P¼0.15), but
there were smaller differences for other causes: treatment-related
deaths (6 vs 3), and pulmonary disease (4 vs 0), which also
contributed to the total excess risk. Four of the 23 cardiovascular
deaths occurred within 40 days after the end of the initial
treatment; all others occurred after 150 days (13 after 1 year).
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Figure 1 (A) Risk of locoregional relapse, by treatment. Estimates
shown are the absolute risk differences: combined modality therapy (CMT)
minus radiotherapy (RT) alone (95% confidence interval (CI)). Number of
locoregional relapses: RT alone: 151; CMT: 84 (excludes deaths and
relapses within 6 weeks from the end of initial treatment). Hazard ratio
(HR): 0.46 (95% CI: 0.35–0.60). (B) Relapse-free survival, by treatment.
Estimates shown are the absolute risk differences: CMT minus RT alone
(95% CI). Median: RT alone: 1.3 years; CMT: 4.6 years. HR: 0.70
(95% CI: 0.58–0.84).
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Figure 2 Overall survival, by treatment. The estimates shown are the
absolute risk differences: combined modality therapy (CMT) minus RT
alone (95% confidence interval (CI)). Median: RT alone: 5.4 years; CMT: 7.6
years. Hazard ratio (HR): 0.86 (95% CI: 0.70–1.04).
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in the CMT group overall (Table 1), 34 vs 18 (P¼0.03), of which 8
vs 2 occurred in the first 5 years and 26 vs 16 occurred after 5 years
(many were lung cancer, 17 vs 7).
DISCUSSION
The present analysis has important differences compared with the
initial report in 1996. With 405 deaths compared with 236 deaths
previously, and a median follow-up of 13 years instead of 3.5 years,
we can provide estimates of the effect of chemoradiation at specific
time points several years after the start of treatment. To our
knowledge, there are no other published long-term follow-up data
on chemoradiation and anal cancer from a large randomised trial.
We have also shown that there is an excess of non-anal cancer
deaths in the first few years after treatment, which diminishes
by 10 years.
Our long-term data confirm the treatment effects we previously
reported in 1996. The HRs in the earlier analysis compared with
those reported here are locoregional failure 0.54 and 0.46, death
from anal cancer 0.71 and 0.67, and OS 0.86 for both analyses.
However, and more importantly, we further show that the full
benefit can be seen by about 5 years after the start of treatment and
this is sustained at least 7 years later. Twelve years after starting
treatment, for every 100 patients given CMT, there are 25.3 fewer
patients with a locoregional recurrence, 12.0 more who are alive
and relapse free, 5.6 more who are alive and 12.5 fewer deaths from
anal cancer, compared with 100 patients given RT alone. These data
provide reassurance to both anal cancer patients and clinicians that
CMT treatment is associated with long-term clinical benefits.
In all, 84% of recurrences are detected within the first 2 years.
Although this is perhaps not surprising for squamous cell
carcinoma, it has not been emphasised previously in the literature.
It is difficult to be certain that tumours that relapse locally after
3 years are true recurrences, or should be regarded as second
primary tumours.
Our results were statistically significant for all end points, except
OS, which was probably due to the excess of deaths not from anal
cancer in the CMT group in the first 5 years. However, the upper
limit of the 95% CI for the OS HR was 1.04, close enough to unity
to suggest that there is likely to be a beneficial effect of CMT.
Most anal cancer deaths occurred in the first few years (53% in the
first 2 years) as expected, and patients who survive to 5 years
might be considered cured and therefore more likely to die from
other causes after this time.
The ACT I data are consistent with other anal cancer trials using
5-fluorouracil and mitomycin in conjunction with radiotherapy.
Five-year locoregional recurrence rates were 32% in ACT I, 33% in
the EORTC study (Bartelink et al, 1997) and 25% in a study from
the United States (Ajani et al, 2008). In an earlier US study, 4-year
locoregional recurrence was 16% (Flam et al, 1996).
There was an increase in the risk of death from causes other
than anal cancer in the first 5 years among patients in the CMT
group, but this is relatively small when considering the large
reduction in deaths from anal cancer. Cardiovascular toxicity,
either during or shortly after completion of chemotherapy, was
a moderate cause of death. Several chemotherapy agents have
cardiotoxic effects, including 5-fluorouracil and mitomycin
(Cunningham et al, 2008; Daher and Yeh, 2008; Viale and
Yamamoto, 2008). Common complications are ischaemia, myo-
cardial infarction, thrombosis and hypertension. Several potential
mechanisms have been proposed that might account for cardio-
vascular toxicity, including dysfunction or damage of endothelial
cells, increased platelet aggregation and modulation of nitric oxide
levels (Daher and Yeh, 2008).
The difference in the occurrence of second malignancies may be
partly explained by more patients in the CMT group living longer
than those in the RT group, hence their cumulative risk of
developing a new tumour increases with age. This is consistent
with studies that show that younger age is a risk factor for the
formation of second malignancies (Schwager et al, 2000; Tubiana,
2009). There were nearly twice as many deaths due to second
malignancies in the CMT arm (34 vs 18 RT alone), most occurring
after 5 years. About half were lung cancer (17 CMT vs 7 RT alone),
which may reflect the shared role of smoking in the aetiology of
anal cancer and lung cancer (Frisch et al, 1999; Daling et al, 2004).
An excess of second malignancies has also been noted after
administration of alkylating agents such as mitomycin C (Myerson
et al, 1995), although the effect is not consistently seen across
studies (Zakotnik et al, 2007).
There were no colostomies recorded after November 1995, and
this information was not routinely collected after 2000. This is a
limitation of our analysis. However, for colostomy-free survival,
the time-to-event curve and event rates are similar to those for
RFS. This is not surprising, as only 28% of colostomies occurred
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first relapse after the first year.
Patients were generally staged clinically rather than radiologi-
cally, as were most other trials at the time (including the EORTC
22861 and RTOG 87-04 trials), as they predate the use of
transrectal ultrasound and magnetic resonance imaging. Patients
in the ACT I trial were likely to be understaged, owing to the lack
of a surgical specimen after chemoradiation for histopathological
staging, particularly in the case of microscopic involvement of
non-palpable lymph nodes. The lack of radiological staging and
the different TNM system in the trial (UICC 1985), based on
anatomical extent, rather than size, make comparisons with
modern trials difficult to interpret.
Although ACT I started more than 20 years ago, and was based
on combining radiotherapy with 5-fluorouracil and mitomycin C,
subsequent research conducted since then has not found
chemotherapy regimens that are substantially more effective at
improving local and distant control. Two large anal cancer trials
examined whether cisplatin could be used instead of mitomycin. In
the RTOG 98-11 trial from the United States (Ajani et al, 2008;
N¼682), there was no evidence of a difference in disease-free
survival among those administered 5-fluorouracil plus cisplatin
compared with those administered 5-fluorouracil plus mitomycin;
HR 1.20, 95% CI 0.93–1.55. However, cisplatin was associated with
a significantly higher colostomy rate (19 vs 10%, P¼0.02). The
preliminary results of the second UK Anal Cancer Trial (ACT II;
James et al, 2009; N¼940) suggest a 95% response rate for either
mitomycin or cisplatin. Both trials concluded that cisplatin offered
no additional benefit to patients, other than lower haematological
toxicity. The ACT II study will have a more thorough reporting of
cardiovascular toxicities and second malignancies.
In conclusion, long-term follow-up of ACT I confirms that the
lower local failure rate and improvements in RFS for anal cancer
following chemoradiation are maintained even 12 years after
starting treatment. Only 7% (39) of patients developed metastatic
disease without earlier locoregional relapse; hence the focus of
treatment should concentrate on locoregional control. It is also
striking that there were only 11 further locoregional relapses after
5 years. For this reason, 3-year or perhaps 5-year RFS might
represent a satisfactory alternate early end point than OS, and
seems to be more relevant in a population with a median age of 64
years. This finding also questions the relevance of stringent follow-
up after several years have elapsed.
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Table A1 Summary results on efficacy
Event RT alone CMT
Locoregional relapse rate (%) at
3 years 53.4 29.7
5 years 57.1 32.3
10 years 59.1 33.8
12 years 59.1 33.8
Relapse-free survival rate (%) at
3 years 38.4 51.1
5 years 33.7 46.6
10 years 23.5 36.2
12 years 17.7 29.7
Colostomy-free survival rate (%) at
3 years 40.5 50.4
5 years 36.8 46.9
10 years 25.6 35.6
12 years 20.1 29.6
Overall survival rate (%) at
3 years 60.0 64.6
5 years 53.0 58.1
10 years 35.8 41.5
12 years 27.5 33.1
Anal cancer death rate (%) at
3 years 35.9 25.9
5 years 41.8 30.5
10 years 47.7 35.3
12 years 48.7 36.2
Abbreviations: CMT¼combined modality therapy; RT¼radiotherapy.
Table A2 Type of event, by time to event and treatment
0–1.9 years 2.0–4.9 years 5.0–9.9 years 10+ years
Event
RT alone
(N¼285)
CMT
(N¼292)
RT
alone CMT
RT
alone CMT
RT
alone CMT
First event: relapse or death
Locoregional relapse 136 79 14 9 4 5 1 1
Distant relapse 16 19 4 5 1 3 0 2
Locoregional relapse and distant relapse 6 6 1 1 0 0 0 0
Death 5 11 6 17 20 24 25 31
Any event 163 115 25 32 25 32 26 34
Cause of death
Anal cancer 68 47 44 30 12 13 1 3
New cancer 0 3 2 5 9 9 7 17
Treatment related 3 5 0 1 1 0 1 0
Other causes 7 14 4 14 17 15 22 21
Cardiac 1 3 2 5 7 5 8 7
Cerebrovascular accident 2 3 0 2 1 0 2 1
Other vascular 2 2 1 0 0 1 0 0
Infection 0 2 1 1 5 6 9 8
Pulmonary 0 1 0 3 3 2 2 3
Other 2 3 0 3 1 1 1 2
Unknown 3 0 0 1 2 0 2 2
Total 81 69 50 51 41 37 33 43
Abbreviations: CMT¼combined modality therapy; RT¼radiotherapy.
Table A3 Late morbidities
%( n)
Late morbidity type RT alone (N¼281) CMT (N¼284) P-value
Ulcers/radionecrosis 6 (18) 8 (23) 0.44
Anorectal 27 (76) 29 (81) 0.70
Genitourinary 4 (11) 4 (11) 0.98
Skin 18 (51) 21 (59) 0.43
Abbreviations: CMT¼combined modality therapy; RT¼radiotherapy.
Number at risk: 
RT alone : 285 132 101 86 64 47 31 24 12
CMT: 292 178 147 130 98 62 42 20 8
100
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+10.1% (3.3 – 16.6)
10-year:
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12-year:
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Figure A1 Colostomy-free survival, by treatment. Estimates shown are
the absolute risk differences: combined modality therapy (CMT) minus
RT alone (95% confidence interval (CI)). Median: RT alone: 1.8 years; CMT:
4.7 years. Hazard ratio (HR): 0.76 (95% CI: 0.63–0.91).
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